STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

hCG

Also known as

Human chorionic gonadotropin · HCG · Pregnyl · Novarel · Profasi (historical urinary brand discussion) · Ovidrel / choriogonadotropin alfa (recombinant) · r-hCG · u-hCG · chorionic gonadotropin · beta-hCG (assay/doping talk) · Gonasi (regional brand talk) · choriogonadotropin alfa

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Some talk Systemic SubQ / IM Reproductive & endocrine peptides

Systemic — LH/CG-receptor agonist on Leydig cells (males) and theca/granulosa (females); raises gonadal steroids axis-wide, not a local cosmetic peptide.

What people say Human chorionic gonadotropin is a glycoprotein hormone used clinically as an LH-receptor agonist. In males it can stimulate Leydig-cell testosterone production, while spermatogenesis still depends on FSH and testicular context. Doses people talk about
TRT-adjunct community bandAbout 250–500 IU subcutaneously two or three times weekly

Community/clinic discussion; the checked adverse account used 250 IU three times weekly alongside daily testosterone cypionate.

Coviello ITT study arms125, 250 or 500 IU hCG subcutaneously every other day for three weeks

Twenty-nine healthy men also received testosterone enanthate 200 mg weekly; 200 mg was not an hCG amount.

Fertility induction contextAbout 1,500–2,000 IU two or three times weekly in the preserved clinical range

Multi-month specialist-managed context; one forum author reported 1,500 IU three times weekly after stopping long-term TRT, with simultaneous supplement and lifestyle changes.

These contexts answer different questions and are not a titration sequence or individualized medical instructions.

Half-life & effect duration

Half-life in the body
  • Single injected dose · urinary hCGAbout 36.8 hours
  • Single injected dose · recombinant hCGAbout 38.6 hours
  • Long-term treatment · effective half-lifeAbout 5.8 days
Felt duration people report
  • Immediate reportsLittle sensation, or rapid adverse effects in one TRT-adjunct account
  • Fertility changesAssessed over months; one account described changes between months 3 and 6
Timing context & sources
How it may feel Experience is not uniform: many report little immediate sensation, while one TRT-adjunct account described rapid water retention, brain fog, libido loss and higher blood pressure on repeated re-challenges. Fertility outcomes are assessed over months, not injection-day sensation.
Cycles people discuss The preserved profile mixes short bodybuilding PCT blocks, ongoing TRT co-therapy and multi-month fertility treatment. These are distinct goals and clinical contexts, not interchangeable cycles. Timing TRT-adjunct talk commonly uses Monday/Thursday or Monday/Wednesday/Friday calendars. Morning versus evening and training-day choices are preferences rather than a demonstrated winner; consistency and the timing of lab sampling are the practical focus. Stacks Testosterone co-treatment, clomiphene and FSH/hMG appear in distinct clinical or community contexts. Each changes attribution and should not be collapsed into an hCG-only outcome. Watch for Estrogenic / gyno: Breast tenderness or gynecomastia via T→E2 aromatization (testicular + peripheral); mono series note nipple sensitivity/breast swelling in a minority, often improving with dose cut or AI/SERM.
Related
ClomipheneEnclomipheneGonadorelinKisspeptin-10Anastrozole

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

A 2022 healthy-women study reported mean terminal half-lives of 36.77 hours for urinary hCG 10,000 IU and 38.63 hours for recombinant hCG 250 mcg/6,500 IU after single subcutaneous doses.

A separate male study found that subcutaneous administration delayed peak concentration and prolonged half-life compared with intramuscular administration, but its abstract did not report numerical values.

The 36.77–38.63 hour values come from high single doses in healthy women and two specific products; they should not be generalized to low-dose male TRT adjunct use, repeated dosing or biological-effect duration.

Half-life in the body

A 2024 population analysis estimated a pooled effective serum hCG half-life of 5.8 days during long-term subcutaneous treatment in gonadotrophin-deficient men.

The analysis used 502 serum samples from 52 men receiving urinary hCG, routinely 1,500 IU, or recombinant hCG, routinely 62.5 mcg, with higher amounts in some patients. It describes repeated-treatment effective exposure, not a single-dose terminal phase.

Observational multidose therapeutic sampling, heterogeneous amounts and body size, and population regression in gonadotrophin-deficient men prevent substitution for the 36.77–38.63-hour single-dose healthy-women result or for felt, testosterone-response or fertility-outcome duration.

Felt duration people report

There is no single felt-duration window: some users report little immediate sensation, one TRT-adjunct user reported rapid adverse effects on repeated challenges, and fertility outcomes are assessed over months.

A fertility forum author described semen changes between three and six months after stopping long-term TRT and using clinician-directed hCG, but also changed supplements and lifestyle; the adverse report included daily testosterone.

Anonymous reports, concurrent testosterone or supplements, changing lifestyle, no blinded causality assessment and outcome-specific clocks prevent a universal onset or duration estimate.

  • Reddit r/Testosterone — hCG side effects (opens in a new tab)Original post and replies: daily testosterone cypionate plus hCG 250 IU Monday/Wednesday/Friday; repeated reports of water retention, brain fog, libido loss and higher blood pressure, with other commenters describing varied symptoms.Unverified products, concurrent testosterone, anonymous self-reporting, no standardized adverse-event assessment and substantial responder-selection bias.
  • Reddit r/maleinfertility — Three-month to six-month hCG semen-analysis results (opens in a new tab)Original post and same-author replies: long-term TRT cessation, urologist-directed 1,500 IU hCG three times weekly and reported semen changes at three and six months.Single uncontrolled report with simultaneous vitamins and lifestyle changes; image-based laboratory results were not independently adjudicated and natural recovery after TRT cessation is a major confounder.

Other context in this card

What people say 15

  • TRT testicular size: Low-dose adjunct commonly linked to less atrophy / better fullness vs TRT alone. forum
  • PCT “wake-up”: Short high-ish blocks used to stimulate suppressed testes before/with SERMs after AAS so the testes are responsive when endogenous LH returns. forum
  • Libido / sexual function: Some report better libido/ED symptoms when gonadal output or ITT improves — confounded by T/E2/sleep/placebo. forum
  • Well-being anecdotes: Mood/drive claims common; hard to separate from concurrent TRT, training, and E2. anecdote
  • Intratesticular T (ITT): Coviello et al. (JCEM 2005): healthy men on TE 200 mg/wk + placebo or hCG 125 / 250 / 500 IU SC every other day × 3 weeks; ITT fell ~94% on T alone; rose dose-dependently with hCG — 125 IU group ~25% below baseline, 250 IU ~7% below, 500 IU group ~26% above baseline ITT. trial
  • Serum T on suppressed men: Same study — 250 and 500 IU EOD groups often pushed circulating T above normal while rescuing ITT. trial
  • Fertility on TRT: Concurrent low-dose hCG discussed to keep sperm production from fully collapsing under exogenous T; clinic series of men on TRT + ~500 IU EOD without progressing to azoospermia, with pregnancies reported. trial
  • 17-OHP as ITT proxy: Amory et al. and related work — serum 17-hydroxyprogesterone tracks ITT changes when hCG is added to T suppression; used in clinic talk as a non-invasive ITT signal. trial
  • Sperm recovery contexts: hCG alone or + FSH/hMG/clomiphene/tamoxifen/anastrozole in androgen-suppression or hypogonadotropic recovery; multi-center recovery series often quote mean ~4 months to usable sperm concentration after high-dose hCG ± adjuvants post-TRT/AAS. trial
  • Spermatogenesis recovery after T: Stocks/Lipshultz-era regimens (e.g. 3,000 IU hCG + 75 IU FSH three times weekly) associated with high rates of improved counts in men with prior testosterone use, including some who stayed on concurrent T. trial
  • hCG monotherapy (selected men): Clinic series (e.g. Madhusoodanan et al.) — symptomatic men on average ~2,000 IU weekly for ~6 months; mean T rise ~360 → ~520 ng/dL (~60%), ~50% reported symptom improvement; framed as option when fertility preservation or avoiding classic TRT side-effect profile is prioritized. trial
  • Mono starting band (clinic talk): Starting ~1,500 IU three times weekly, titrated on labs/symptoms; broad LH baselines can still respond if testes work. trial
  • Female ART trigger: Standard single high-dose trigger for final oocyte maturation / ovulation timing. trial
  • Cryptorchidism / puberty history: Labeled pediatric/male endocrine uses in selected cases (historical and clinical). trial
  • What it does not do alone: Full spermatogenesis often still needs FSH/hMG or intact pituitary FSH; hCG is LH-mimetic only. trial

Doses people talk about 27

  • Practical translation of Coviello: ~500 IU every other day is the modern reference point for “ITT maintenance under T suppression”; forums often approximate with ~500 IU 3×/week or 250–500 IU 2–3×/week. forum
  • TRT micro / size-fertility adjunct (common clinic/forum band): ~250–500 IU SC two to three times per week. forum
  • Crisler-style classic TRT talk: ~250 IU twice weekly widely cited — historically timed the day of and the day before a weekly testosterone cypionate injection so LH-mimetic drive bridged the trough. forum
  • Minimum atrophy-prevention lore: Some clinicians cite ~500 IU/week total as a rough floor for size; half-life arguments favor splitting ≥2×/week over one big weekly shot. forum
  • Monday/Thursday or M/W/F splits: Practical 2–3×/week calendars dominate TRT co-therapy talk. forum
  • Daily micro lore (older forum protocols): ~100 IU ED on-cycle for “preservation of sensitivity,” sometimes dropped ~2 weeks before AAS clear — niche vs mainstream 2–3×/week micro. forum
  • PCT moderate band: ~500–1,000 IU every other day for ~10–16 days, then transition toward SERMs. forum
  • PCT alternate moderate: ~250–500 IU 2–3×/week for ~2–3 weeks before or briefly overlapping early SERM phase. forum
  • PCT aggressive / deep-suppression talk: ~1,500–2,500 IU EOD or ~2,500 IU twice weekly for short limited blocks — higher desensitization and E2 concern. forum
  • On-cycle AAS preservation (modern forum culture): often ~250–500 IU 2×/week throughout the cycle; goal is size + easier restart, not superphysiological mega-IU. forum
  • Bodybuilding “high” on-cycle quotes: ~1,000–3,000 IU 1–3×/week appears in secondary guides — not the modern low-dose consensus; older charts even quoted 2,500–5,000 IU 1–2×/week and are now heavily criticized. forum
  • If continuous on-cycle micro was used: many charts say skip or minimize high-dose PCT hCG and go straight to SERMs so Leydig cells re-sensitize to endogenous LH. forum
  • Alternate TRT adjunct quotes: ~500–1,000 IU/week total split 2–3×; some clinics start 250 IU 2×/week and step up; Hone-style public education often quotes ~500–1,500 IU 2–3×/week depending on goal. forum
  • Units: Male multi-dose vials dosed in IU, not mcg; confusing Ovidrel mcg labeling with Pregnyl IU is a known mix-up. forum
  • Landmark ITT study (Coviello 2005): Healthy men on TE 200 mg/wk + placebo or hCG 125 / 250 / 500 IU SC every other day × 3 weeks; ITT collapsed ~94% on T alone; linear ITT rescue with hCG; 500 IU EOD group finished ~26% above baseline ITT. trial
  • EOD TRT + fertility planning: ~500 IU every other day frequently quoted from urology/andrology summaries for men keeping TRT while prioritizing nearer-term fertility. trial
  • Lipshultz-style size-only floor: ~1,500 IU once weekly cited when the only goal is preventing atrophy (less preferred than split dosing for many). trial
  • Lipshultz-style future pregnancy on TRT: typically ~500 IU SC three times per week concurrent with testosterone. trial
  • Lipshultz-style nearer pregnancy: often come off TRT (or aggressively cover with high hCG); examples include ~3,000 IU EOD or ~3,000 IU three times weekly ± clomiphene (e.g. 25 mg daily during bridge blocks); FSH added if semen/FSH still inadequate after months. trial
  • Twice-yearly “reset” education (clinic lore): cycle off testosterone periodically with a ~4-week block of high hCG (e.g. ~3,000 IU 3×/week) plus clomiphene — education talks, not a universal standard of care. trial
  • Male-infertility clinic high-dose band: ~1,000–4,000 IU three times per week SC/IM; post-high-dose androgen stop often starts near ~3,000 IU 3×/week + SERM. trial
  • HH induction (clinical ranges): commonly ~1,500–2,000 IU 2–3×/week to normalize T, then months of monitoring; some protocols span ~1,500–5,000 IU 2–3×/week for 3–6 months before adding FSH. trial
  • hCG mono then +FSH: Common HH/post-suppression sequence: hCG 2–3×/week for months; add rFSH/hMG (~75–150+ IU, sometimes up to ~400 IU multi×/week) if sperm still absent/poor. trial
  • hCG mono symptom series doses: average ~2,000 IU weekly; starting ~1,500 IU 3×/week with titration. trial
  • Female ART trigger (context only): single large urinary dose historically ~5,000–10,000 IU or recombinant Ovidrel ~250 mcg — completely different product math than male micro-dosing. trial
  • Route: SC or IM both used; modern male self-admin heavily prefers SC (abdomen/thigh); steroidogenic T response considered equivalent in classic PK work. trial
  • Framing: Discussion ranges only — not medical advice, not DIY prescriptions; IU math errors and vial-concentration mistakes are extremely common. forum

How it may feel 8

  • Injection day: Little systemic “feel”; mild site sting possible with SC. forum
  • Days 1–3: Labs and subjective T lag — day-of energy claims unreliable. forum
  • Week 1–2: Some report testicular fullness, morning wood, or libido; many wait for bloodwork. forum
  • Weeks 2–4: Watch estradiol climb, water weight, nipple sensitivity, acne, irritability as T (and aromatization, including testicular aromatase) rise. forum
  • Hours 0–2: Some pharmacodynamic data show an early serum-T bump after IM hCG — not a reliable “same-day energy” cue. trial
  • Hours 48–96: Biphasic T response classic — secondary/larger T peak often ~48–72 hours (some sources extend peak window to ~72–96 hours). trial
  • Weeks 4–8+ fertility: Meaningful semen-parameter moves often take multi-week to multi-month courses, not a few shots; 3–6+ months is common clinic language. trial
  • Months 3–12 fertility induction: HH and post-androgen recovery courses often reassess semen at ~3–4 months before escalating to FSH or changing protocol. trial

Cycles people discuss 10

  • PCT blocks: Usually short — roughly 1–3 (sometimes ~4) weeks of hCG around AAS clearance, not endless high-IU PCT. forum
  • PCT timing culture: Often start after long esters have largely cleared (or bridge only through late clearance); some clinicians say run hCG for ~3–4 weeks after last long-ester shot until ~4–5 half-lives pass, then SERM for 4–8 weeks — charts vary. forum
  • SERM handoff: Classic charts stop or taper hCG then run clomiphene and/or tamoxifen (or enclomiphene) so pituitary LH/FSH can rise — hCG alone does not restore pituitary drive and can keep LH suppressed while on board. forum
  • TRT co-therapy: Continuous multi×/week adjunct for months/years while on testosterone — treated like ongoing medication, not a “blast.” forum
  • Desensitization debate: Very high and/or daily mega-doses are accused of LH-receptor downregulation / Leydig fatigue; low split doses preferred in modern talk; short aggressive blocks still used when restarting after deep suppression. forum
  • On-cycle vs blast-only: Some keep micro-hCG entire AAS cycle for size; others only front-load end of cycle (“blast hCG into PCT”) — both appear in forums; continuous micro often pairs with little/no PCT hCG. forum
  • Re-runs: Common before planned conception or after another suppressive cycle. forum
  • Fertility courses: Often months (3–12+) with semen analysis and dose titration; conception timelines can be longer; some men need two years for full spontaneous recovery after AAS even with help. trial
  • Primary hypogonadism limit: If testes cannot produce T/sperm, hCG will not “fix” TRT or full fertility the way secondary/HH cases can. trial
  • Not a fat-loss cycle: FDA-warned hCG diet products + VLCD are a separate (unsupported) cultural use and should not be confused with endocrine protocols. trial

Timing 12

  • Community “~2 days / ~3.5 days” talk: Bro charts sometimes quote longer biological activity than plasma half-life; used to justify EOD or 2–3× weekly spacing. forum
  • Dosing logic: Longer half-life → multi-day spacing, not continuous infusion; daily micro-dosing discussed but not required for most TRT adjuncts. forum
  • Downstream estradiol: Rising testicular/serum T aromatizes (including testicular aromatase) → E2, water, gyno risk; AIs/SERMs discussed when labs/symptoms demand, not by default. forum
  • Injection timing culture: AM vs PM or training-day splits — no strong head-to-head; consistency and lab timing matter more. forum
  • Labs to track: Total/free T, estradiol, hematocrit/CBC, PSA per clinic norms, FSH/LH context, sometimes 17-OHP as ITT proxy, and semen analysis when fertility is the goal — not energy alone. forum
  • Single-dose SC context: A 2022 bioavailability study in healthy women reported mean terminal half-lives of 36.77 ± 5.11 hours for urinary hCG 10,000 IU and 38.63 ± 6.08 hours for recombinant hCG 250 mcg/6,500 IU. Saal's male study found delayed peak and prolonged half-life after SC versus IM but its abstract gives no numerical value. trial
  • Repeated-treatment effective half-life: Handelsman et al. (2024) derived a pooled 5.8-day effective serum hCG half-life from 502 samples in 52 gonadotrophin-deficient men receiving long-term subcutaneous urinary or recombinant hCG. This population regression is not the single-dose terminal half-life measured in healthy women. trial
  • vs LH: Endogenous LH half-life ~20–30 minutes — impractical as a therapeutic LH stand-in; hCG’s longer action enables EOD / 2–3× weekly. trial
  • T response lag: Peak serum testosterone often delayed to ~48–96 hours post-injection (biphasic early + secondary peak) — do not judge a protocol by same-day “feel.” trial
  • SC vs IM PK: Peak serum hCG higher/faster IM in some data; SC peak delayed and half-life longer; testicular steroidogenic T response similar after equal IU. trial
  • Downstream HCT: Hematocrit can rise with androgen drive; frank polycythemia rates often described as lower than classic high-dose TRT but still monitored (series note rare HCT >54). trial
  • Anti-doping window talk: Urinary immunoassay detection discussed on the order of ~7–10+ days after use in doping literature (assay- and dose-dependent); full clearance talk sometimes extends toward ~2 weeks (4–5 half-lives of the short framing). trial

More on what it is 11

  • Why people care: Keeps testes “on” under exogenous androgens, supports ITT/sperm talk, classic PCT restart, real fertility medicine, and selected hCG mono for hypogonadal symptoms without classic TRT. forum
  • Research lens: Forum IU charts and clinic fertility protocols are different worlds — community ranges ≠ supervised regimens. forum
  • What it is: Pregnancy glycoprotein hormone; clinical LH-mimetic (LHCG / LHCGR agonist). trial
  • Mechanism (males): Binds LH receptors on Leydig cells → testosterone + supports spermatogenesis when FSH/axis context allows. trial
  • Mechanism (females / ART): Mimics mid-cycle LH surge → final oocyte maturation / ovulation trigger. trial
  • vs native LH: Same receptor family but much longer half-life than LH (~20–30 minutes), so practical multi-day dosing. trial
  • Evidence tier: Labeled fertility/hypogonadism drug (Pregnyl/Novarel-class and recombinant Ovidrel) — not a pure gray-market “research peptide” story. trial
  • Not a: Steroid, SERM, AI, or testosterone replacement — needs functioning gonadal tissue to work; does not replace FSH. trial
  • Urinary vs recombinant: u-hCG (Pregnyl/Novarel-class from pregnancy urine) vs r-hCG/Ovidrel (lab-made); clinical effect largely equivalent in male and ART contexts; packaging and unit systems differ (IU vs mcg). trial
  • Sport note: Gonadotropins prohibited in male athletes (WADA); urine immunoassays detect exogenous hCG; positive findings require medical workup to exclude pathology (e.g. tumor). trial
  • Weight-loss lore: “hCG diet” (injectable or homeopathic drops + very-low-calorie diet) is a separate, FDA-warned cultural track with no approved weight-loss indication — not the TRT/fertility discussion. trial

Stacks 12

  • TRT + hCG: Core real-world stack for hypogonadism treatment plus fertility/testicular volume goals. forum
  • PCT: hCG → SERM: Short hCG block then clomiphene and/or tamoxifen (sometimes brief overlap) — classic AAS recovery charting; enclomiphene increasingly substituted in modern talk. forum
  • PCT trio talk: hCG + SERM ± AI when E2 spikes on restart — AI not automatic. forum
  • AI adjacency: Anastrozole/exemestane talk if high-E2 symptoms or labs on hCG-driven T rise — not automatic for every user. forum
  • SERM for gyno risk: Tamoxifen sometimes discussed if nipple sensitivity appears while keeping hCG; dose reduction is the other lever. forum
  • AAS on-cycle + micro-hCG: Bodybuilding preservation stack to reduce shutdown atrophy during the cycle itself. forum
  • Kisspeptin / gonadorelin adjacency: Upstream GnRH-path agents discussed as different tools; not interchangeable IU-for-IU with hCG (hCG bypasses pituitary and hits testes directly). forum
  • hCG + clomiphene (fertility-on-TRT education): Dual approach to support ITT and try to raise FSH when pregnancy is planned (e.g. high hCG EOD + clomiphene EOD in some staged protocols). trial
  • hCG + FSH or hMG: When sperm needs Sertoli/FSH drive beyond LH-mimetic stimulation alone (HH and refractory post-androgen cases); example recovery regimen 3,000 IU hCG + 75 IU FSH 3×/week. trial
  • hCG + tamoxifen / anastrozole adjuvants: Used in post-TRT recovery series alongside high-dose hCG when counts remain low. trial
  • Enclomiphene / clomiphene alternative framing: Oral SERMs compared vs hCG±TRT for secondary hypogonadism when injections unwanted or fertility is the primary goal. forum
  • Not stacked with “hCG diet” oral drops: Unrelated unsupported weight-loss product class. trial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 21

  • Acne / oily skin: Androgen drive can worsen acne in susceptible users. forum
  • Product quality risk: Compounded/research-labeled powders may not match labeled IU; under/over-dosing and contaminants possible. forum
  • DIY AAS-adjacent risk: Unsupervised stacking without labs (E2, HCT, semen, fertility goals) is a structural failure mode. forum
  • Prostate / androgen caution: Androgen drive discussions always include PSA monitoring norms in older men under clinic care. forum
  • Estrogenic / gyno: Breast tenderness or gynecomastia via T→E2 aromatization (testicular + peripheral); mono series note nipple sensitivity/breast swelling in a minority, often improving with dose cut or AI/SERM. trial
  • Water retention / weight feel: Androgen/estrogen-related sodium and fluid retention reported. trial
  • Injection site: Pain, redness, swelling, bruising at SC/IM sites; urinary products sometimes more local reaction talk than recombinant pens. trial
  • Mood / neuro: Headache, irritability, restlessness, insomnia, mood swings, depression notes on labels/series. trial
  • GI: Nausea, stomach discomfort, vomiting in some. trial
  • Hematocrit: Can rise; polycythemia less emphasized than high-dose TRT but CBC monitoring still discussed. trial
  • Thrombosis (rare): Labeling and safety reviews note rare thrombotic events — low frequency, high seriousness. trial
  • Blood pressure / edema: Hypertension and swelling listed among less common effects. trial
  • High-dose desensitization: Pharmacologic LH/hCG can downregulate Leydig signaling — core argument against mega-IU daily/EOD forever and for stopping hCG before pure SERM PCT. trial
  • Supraphysiologic T from adjuncts: Even “low” hCG on TRT can push serum T high (Coviello 250/500 IU groups) — labs required. trial
  • Female OHSS: Ovulation-trigger doses linked to ovarian hyperstimulation syndrome risk in ART. trial
  • Pregnancy tests: Exogenous hCG can make urine pregnancy tests positive (men included) — expected pharmacology, not “mystery pregnancy.” trial
  • WADA / sport: hCG prohibited in male athletes; adverse findings require medical workup to exclude pathology (e.g. germ-cell tumor). trial
  • No FSH replacement: hCG is not FSH — full spermatogenesis often needs FSH/hMG or intact pituitary FSH when axis is suppressed. trial
  • Primary testicular failure: Limited or no T/sperm response if Leydig/Sertoli function is gone. trial
  • Allergy: Rare hypersensitivity / anaphylaxis risk with injectable biologics. trial
  • hCG diet products: FDA warns against weight-loss hCG (drops/sprays/pellets); not approved for fat loss; VLCD component carries separate medical risk. trial

Updated: 2026-08-12

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →